Company type | Public |
---|---|
Founded | 2002 |
Founder | Eckard Weber |
Headquarters | La Jolla, California, U.S. |
Website |
www |
Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. [1] The company is based in La Jolla, California and was established by Eckard Weber in 2002. [1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. [1]
The company has a single product, Contrave, approved for use in the United States in 2014. [2] [3] Contrave was designed not only to curb hunger but also reduce cravings. [3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering. [2][ unreliable source?]
Orexigen declared bankruptcy in 2018 and was sold to Nalpropion. [4] [5]